FLT3-mutated
Showing 1 - 25 of 1,915
Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)
Suspended
- Acute Myeloid Leukemia With FLT3/ITD Mutation
-
Tampa, FloridaMoffitt Cancer Center
Nov 11, 2022
FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia Trial (midostaurin)
Available
- FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia
- (no location specified)
Oct 18, 2022
Acute Myeloid Leukemia Trial (Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine)
Not yet recruiting
- Acute Myeloid Leukemia
- Gilteritinib 40 MG Oral Tablet
- +4 more
-
Lexington, KentuckyUniversity of Kentucky
Oct 27, 2022
Acute Myeloid Leukemia Trial in Miami (CPX-351, Midostaurin, Busulfan)
Recruiting
- Acute Myeloid Leukemia
- CPX-351
- +5 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health of South Florida
Jul 27, 2022
AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)
Not yet recruiting
- AML, Adult
- +4 more
- AzaCITIDine Oral Tablet
- Xospata
-
Amiens, France
- +19 more
Sep 1, 2023
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in United States (Lanraplenib,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Los Angeles, California
- +3 more
Aug 4, 2022
Acute Myeloid Leukemia (AML) Trial in Chengdu (SKLB1028, Salvage Chemotherapy)
Recruiting
- Acute Myeloid Leukemia (AML)
- SKLB1028
- Salvage Chemotherapy
-
Chengdu, Sichuan, ChinaWest China hospital of Sichuan University
Nov 1, 2021
Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia Trial in Columbus (Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jan 4, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine and
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Decitabine and Cedazuridine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Apr 19, 2022
Acute Myeloid Leukemia Trial in Worldwide (Midostaurin, Placebo)
Active, not recruiting
- Acute Myeloid Leukemia
- Midostaurin
- Placebo
-
Hong Kong, Hong Kong
- +40 more
Jan 20, 2023
Acute Myeloid Leukemia Trial in United States (Gilteritinib, Midostaurin, Daunorubicin)
Active, not recruiting
- Acute Myeloid Leukemia
- Gilteritinib
- +3 more
-
Scottsdale, Arizona
- +43 more
Nov 17, 2022
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations Trial in Canada, Japan, United States (gilteritinib)
Approved for marketing
- Acute Myeloid Leukemia (AML)
- FMS-like Tyrosine Kinase-3 (FLT3) Mutations
-
Los Angeles, California
- +38 more
Apr 18, 2021
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Boston (Iadademstat, Gilteritinib Oral Tablet)
Recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Iadademstat
- Gilteritinib Oral Tablet
-
Boston, Massachusetts
- +2 more
Jan 18, 2023
Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia Trial in Japan, Korea, Republic of, Taiwan (gilteritinib,
Active, not recruiting
- Acute Myeloid Leukemia
- FLT3-mutated Acute Myeloid Leukemia
- gilteritinib
- +2 more
-
Anjo, Aichi, Japan
- +54 more
Jan 10, 2023
Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia Trial in Houston
Recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 13, 2020
Acute Myeloid Leukemia Trial in Houston (Crenolanib besylate, Idarubicin, Cytarabine)
Completed
- Acute Myeloid Leukemia
- Crenolanib besylate
- +7 more
-
Houston, TexasMD Anderson Cancer Center
Jul 17, 2020
Acute Myeloid Leukemia With FLT3/ITD Mutation Trial (XY0206, Salvage Chemotherapy)
Not yet recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- XY0206
- Salvage Chemotherapy
- (no location specified)
May 24, 2023
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations Trial in Worldwide (Crenolanib, Cytarabine,
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Crenolanib
- +6 more
-
Sacramento, California
- +61 more
Apr 28, 2021
Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)
Not yet recruiting
- Leukemia, Acute Myeloid (AML)
- Clifutinib
- +5 more
- (no location specified)
Oct 16, 2022
Acute Myeloid Leukemia Trial in Canada, United States (Midostaurin, Standard of Care)
Completed
- Acute Myeloid Leukemia
- Midostaurin
- Standard of Care
-
La Jolla, California
- +18 more
Mar 12, 2021
Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation Trial (Biospecimen Collection, Bone
Not yet recruiting
- Acute Myeloid Leukemia With KMT2A Rearrangement
- Acute Myeloid Leukemia With NPM1 Mutation
- Biospecimen Collection
- +7 more
- (no location specified)
Jun 1, 2023
Newly Diagnosed FLT3 Mutated AML Trial in United States (Crenolanib, Midostaurin, Cytarabine)
Recruiting
- Newly Diagnosed FLT3 Mutated AML
- Crenolanib
- +3 more
-
Duarte, California
- +30 more
May 21, 2020
FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia Trial in Wuhan (T cell injection targeting FLT3 chimeric antigen
Recruiting
- FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
- T cell injection targeting FLT3 chimeric antigen receptor
-
Wuhan, Hubei, ChinaUnion Hospital, affiliated with TongJi Medical College, HuaZhong
Jun 20, 2022